16.17 USD
↘ 0.27 (1.64%)AT CLOSE (11:59 AM EDT)
Delcath Systems Inc
DCTHNASDAQ • USD
16.18
↗ 0.01 (0.06%)
POST MARKET (AS OF 07:39 PM EDT)
Post Market
AS OF 07:39 PM EDT
16.18
↗ 0.01 (0.06%)
Market: CLOSED
DCTH is currently priced at $16.19. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, DCTH trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Sep 15, 2026.
Open?$16.49
High?$16.49
Low?$15.88
Prev. Close?$16.44
Volume?323.2K
Avg. Volume?618.9K
VWAP?$16.11
Rel. Volume?0.52x
Bid / Ask
Bid?$13.14 × 100
Ask?$18.52 × 100
Spread?$5.38
Midpoint?$15.83
Valuation & Ratios
Market Cap?570.4M
Shares Out?34.7M
Float?27.2M
Float %?78.5%
P/E Ratio?1,072.27
P/B Ratio?4.71
EPS?$0.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Themes
Employees
156
Market Cap
570.4M
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
Listed
2000-10-19
Address
566 QUEENSBURY AVENUE
QUEENSBURY, NY 12804
Phone: (518) 743-8892
QUEENSBURY, NY 12804
Phone: (518) 743-8892
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?100
Momentum?73
Short Sent.?60
Piotroski F-Score?3/9Weak
Altman Z-Score?17.86Safe
Confidence?53%Low
Short InterestElevated
Short % of Float?8.23%Elevated
Short Interest?2.2M
Days to Cover?5.0
Free Float27.2M
Avg Daily Volume451.4K
Settlement Date2026-08-31
Financial Health
Current Ratio?9.83Strong
Quick Ratio?8.95Strong
Cash Ratio?3.58Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?1,072.3PRICEY▾
Peers100
S&P3
P/B?4.71FAIR▾
Peers100
S&P39
P/S?5.98FAIR▾
Peers100
S&P22
P/FCF?32.6FAIR▾
Peers100
S&P25
EV/EBITDA?-359.4CHEAP▾
S&P97
EV/Sales?5.48FAIR▾
Peers100
S&P32
Returns & Efficiency
ROE?0.4%WEAK▾
Peers50
S&P15
ROA?0.4%WEAK▾
Peers50
S&P9
Cash Flow & Enterprise
FCF?$17.5M
Enterprise Value?$522.9M
Fundamentals ratios updated end of day